Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is anticipated to initiate a Phase 2 clinical trial in the first half of 2025 for the treatment of idiopathic pulmonary fibrosis. Rein’s second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the U.S. and E.U. and Fast Track Designation in the U.S. 

For more information, please visit www.reintx.com or follow us on Twitter at @Rein_Tx.


Rein Therapeutics

Org chart

Teams

Offices

Rein Therapeutics

Org chart

Teams

Offices

Related companies